Recommendations for NACT are seemingly uncomplicated in women with high‐risk tumor biology who will receive clear benefit (i.e., large tumor‐to‐breast ratio, axillary node‐positive disease, HER2+ or TNBC with tumors ≥2 cm). The gene discussed is ERBB2; the disease is neoplasm.